The invention relates to compositions of inhaled drugs, produced in the form of a dry powder for inhalation and shown for the treatment of obstructive respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In particular, the invention relates to inhaled drugs containing the first powder containing budesonide or its pharmacologically acceptable salt in an amount of more than 5 wt.% By weight of said first powder, leucine in an amount of from 5 to 70 wt.% By weight of said first powder, lactose in an amount of from 20 to 90 wt.% from the mass of said first powder； the second powder containing formoterol or its pharmacologically acceptable salt in an amount of more than 1 wt.% by weight of the said second powder, leucine in an amount of from 5 to 70 wt.% by weight of the said second powder, lactose in an amount of from 20 to 90 wt.% from the mass of the said second powder； and a third powder containing a mixture of the first lactose powder with a median of particle size distribution X50 from 35 to 75 microns and a second lactose powder with a median particle size distribution of X50 from 1.5 to 10 microns, with the content of said first and second lactose powders in said the mixture is respectively from 85 to 96% and from 4 to 15%. The specified drug has a highly dispersed fraction (VDF) of more than 60% and the delivered fraction (DF) of more than 80%.Изобретение относится к составам ингаляционных лекарственных препаратов, выпускаемых в форме сухого порошка для ингаляционного введения и показанных для лечения обструктивных заболеваний дыхательных путей, таких как астма и хроническое обструктивное заболевание легких (ХОЗЛ). В частности, изобретение относится к ингаляционным лекарственным препаратам, содержащим первый порошок, содержащий будесонид или его фармакологически приемлемую соль в количестве более 5 вес.% от массы упомянутого первого порошка, лейцин в количестве от 5 до 70 вес.% от массы упомянутого первого порошка, лактозу в кол
